Downregulation of lipogenesis and fatty acid oxidation in the subcutaneous adipose tissue of morbidly obese women

Obesity

Volumn 22, Issue 9, 2014, Pages 2032-2038

  Auguet, Teresa ^a,b   Guiu Jurado, Esther ^a   Berlanga, Alba ^a   Terra, Ximena ^a   Martinez, Salomé ^b   Porras, José Antonio ^b   Ceausu, Andra ^b   Sabench, Fátima ^c   Hernandez, Mercé ^c   Aguilar, Carmen ^a   Sirvent, Joan Josep ^b   Castillo, Daniel Del ^c   Richart, Cristõbal ^a,b  

^a INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^c HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CD36 ANTIGEN; FAS ANTIGEN; FATTY ACID BINDING PROTEIN 4; INSULIN; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; FATTY ACIDS; TUMOR NECROSIS FACTOR-ALPHA;

ACC1 GENE; ADIPONECTIN GENE; ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CD36 GENE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOWN REGULATION; FABP4 GENE; FAS GENE; FATTY ACID OXIDATION; FEMALE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IL6 GENE; INSULIN BLOOD LEVEL; INTRAABDOMINAL FAT; LIPOGENESIS; LXR ALPHA GENE; MAJOR CLINICAL STUDY; OBESITY; PPAR ALPHA GENE; PPAR DELTA GENE; PPAR GAMMA GENE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SPANIARD; SREBP1C GENE; SUBCUTANEOUS FAT; SYSTOLIC BLOOD PRESSURE; TNF ALPHA GENE; WAIST CIRCUMFERENCE; ADIPOGENESIS; CASE-CONTROL STUDIES; COMPLICATION; DIABETES MELLITUS, TYPE 2; DOWN-REGULATION; GENE EXPRESSION REGULATION; GENETICS; HUMANS; INTRA-ABDOMINAL FAT; LIPID METABOLISM; METABOLISM; MIDDLE AGED; OBESITY, MORBID; OXIDATION-REDUCTION;

ADIPOGENESIS; ADULT; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DOWN-REGULATION; FATTY ACIDS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTRA-ABDOMINAL FAT; LIPID METABOLISM; LIPOGENESIS; MIDDLE AGED; OBESITY, MORBID; OXIDATION-REDUCTION; SUBCUTANEOUS FAT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84906935777     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20809     Document Type: Article

References (40)

1. Bluher M,. Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best Pract Res Clin Endocrinol Metab 2013; 27: 163-177.
2. Lean ME,. Pathophysiology of obesity. Proc Nutr Soc 2000; 59: 331-336.
3. Van Gaal LF, Mertens IL, De Block CE,. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444: 875-880.
4. Blüher M,. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes 2009; 117: 241-250.
5. Bays HE,. Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating «sick fat» through improving fat function with antidiabetes therapies. Am J Cardiol 2012; 110: 4B-12B.
6. Vázquez-Vela ME, Torres N, Tovar AR,. White adipose tissue as endocrine organ and its role in obesity. Arch Med Res 2008; 39: 715-728.
7. Sewter C, Berger D, Considine RV, et al. Human obesity and type 2 diabetes are associated with alterations in SREBP1 isoform expression that are reproduced ex vivo by tumor necrosis factor-alpha. Diabetes 2002; 51: 1035-1041.
8. Sekiya M, Yahagi N, Matsuzaka T, et al. SREBP-1-independent regulation of lipogenic gene expression in adipocytes. J Lipid Res 2007; 48: 1581-1591.
9. Mobbs CV, Makimura H,. Block the FAS, lose the fat. Nat Med 2002; 8: 335-336.
10. Loftus TM, Jaworsky DE, Frehywot GL, et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 2000; 288: 2379-2381.
11. Kovacs P, Harper I, Hanson RL, et al. A novel missense substitution (Val1483Ile) in the fatty acid synthase gene (FAS) is associated with percentage of body fat and substrate oxidation rates in nondiabetic Pima Indians. Diabetes 2004; 53: 1915-1919.
12. del Pozo CH, Calvo RM, Vesperinas-Garcia G, et al. Expression profile in omental and subcutaneous adipose tissue from lean and obese subjects. Repression of lipolytic and lipogenic genes. Obes Surg 2011; 21: 633-643.
13. Capurso C, and, Capurso A,. From excess adiposity to insulin resistance: the role of free fatty acids. Vascul Pharmacol 2012; 57: 91-97.
14. Manolopoulos KN, Karpe F, Frayn KN,. Gluteofemoral body fat as a determinant of metabolic health. Int J Obes (Lond) 2010; 34: 949-959.
15. Diraison F, Dusserre E, Vidal H, Sothier M, Beylot M,. Increased hepatic lipogenesis but decreased expression of lipogenic gene in adipose tissue in human obesity. Am J Physiol Endocrinol Metab 2002; 282: E46-E51.
16. Letexier D, Pinteur C, Large V, Frering V, Beylot M,. Comparison of the expression and activity of the lipogenic pathway in human and rat adipose tissue. J Lipid Res 2003; 44: 2127-2134.
17. Minehira K, Vega N, Vidal H, Acheson K, Tappy L,. Effect of carbohydrate overfeeding on whole body macronutrient metabolism and expression of lipogenic enzymes in adipose tissue of lean and overweight humans. Int J Obes Relat Metab Disord 2004; 28: 1291-1298.
18. Hudgins LC, Baday A, Hellerstein MK, et al. The effect of dietary carbohydrate on genes for fatty acid synthase and inflammatory cytokines in adipose tissues from lean and obese subjects. J Nutr Biochem 2008; 19: 237-245.
19. Ranganathan G, Unal R, Pokrovskaya I, et al. The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment. J Lipid Res 2006; 47: 2444-2450.
20. Tinahones FJ, Garrido-Sanchez L, Miranda M, et al. Obesity and insulin resistance-related changes in the expression of lipogenic and lipolytic genes in morbidly obese subjects. Obes Surg 2010; 20: 1559-1567.
21. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014; S1: S81-S90.
22. Terra X, Auguet T, Broch M, et al. Retinol binding protein-4 circulating levels were higher in nonalcoholic fatty liver disease vs. histologically normal liver from morbidly obese women. Obesity 2013; 21: 170-177.
23. Ortega FJ, Mayas D, Moreno-Navarrete JM, et al. The gene expression of the main lipogenic enzymes is downregulated in visceral adipose tissue of obese subjects. Obesity (Silver Spring) 2010; 18: 13-20.
24. Clemente-Postigo M, Queipo-Ortuno MI, Fernandez-Garcia D, Gomez-Huelgas R, Tinahones FJ, Cardona F,. Adipose tissue gene expression of factors related to lipid processing in obesity. PLoS One 2011; 6: e24783.
25. Rorive M, Letiexhe MR, Scheen AJ, Ziegler O,. Obesity and type 2 diabetes. Rev Med Liege 2005; 60: 374-382.
26. Giorgino F, Laviola L, Eriksson JW,. Regional differences of insulin action in adipose tissue: insights from in vivo and in vitro studies. Acta Physiol Scand 2005; 183: 13-30.
27. Kotronen A, Yki-Jarvinen H, Sevastianova K, et al. Comparison of the relative contributions of intra-abdominal and liver fat to components of the metabolic syndrome. Obesity 2011; 19: 23-28.
28. Savage DB, Tan GD, Acerini CL, et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 2003; 52: 910-917.
29. Chong AY, Lupsa BC, Cochran EK, Gorden P,. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 2010; 53: 27-35.
30. Kim JK, Gavrilova O, Chen Y, Reitman ML, Shulman GI,. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem 2000; 275: 8456-8460.
31. Huang-Doran I, Sleigh A, Rochford JJ, O'Rahilly S, Savage DB,. Lipodystrophy: metabolic insights from a rare disorder. J Endocrinol 2010; 207: 245-255.
32. Virtue S, Vidal-Puig A,. It's not how fat you are, it's what you do with it that counts. PLoS Biol 2008; 6: e237.
33. Shoelson SE, Lee J, Goldfine AB,. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801.
34. Yudkin JS,. Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J Obes Relat Metab Disord 2003; 27 (Suppl 3): S25-S28.
35. Das UN,. Is obesity an inflammatory condition? Nutrition 2001; 17: 953-966.
36. Festa A, D'Agostino R Jr, Williams K, et al. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord 2001; 25: 1407-1415.
37. Hotamisligil GS,. Inflammation and metabolic disorders. Nature 2006; 444: 860.
38. Trayhurn P, Wood IS,. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92: 347-355.
39. Poulain-Godefroy O, Lecoeur C, Pattou F, Fruhbeck G, Froguel P,. Inflammation is associated with a decrease of lipogenic factors in omental fat in women. Am J Physiol Regul Integr Comp Physiol 2008; 295: R1-R7.
40. Foster MT, Softic S, Caldwell J, Kohli R, deKloet AD, Seeley RJ,. Subcutaneous adipose tissue transplantation in diet-induced obese mice attenuates metabolic dysregulation while removal exacerbates it. Physiol Rep 2013; 1: e00015.